A new treatment for asthma patients which was trialled at Leicester's Glenfield Hospital has been licensed for use.
It could help to prevent the number of emergency admissions to hospital due to asthma attacks.
Latest figures show that between April 2010 and the end of March 2011 a total of 145 people for every 100,000 adults in the city needed an emergency hospital admission for the condition - the second highest figure in the country.
The drug, used through an inhaler, is intended for adult patients who have suffered one or more severe attacks of asthma in the previous year.
The studies showed that the treatment - Spiriva Respimat - reduced the number of patients who had severe asthma attacks as well reducing the risk of severe attack.
In addition it delayed the time in which the asthma worsened from 181 days to 315 days.
Professor Peter Bradding, a consultant in respiratory medicine at Glenfield Hospital, said: "Over half of asthma patients continue to experience symptoms, despite current treatment options, leaving patients across Leicester and the rest of the East Midlands with a reduced quality of life and an unacceptably high risk of having an asthma attack.
"Asthma attacks are frightening and can occasionally be fatal."
He added: "This new treatment has the potential to reduce asthma symptoms in adult patients and prevent asthma attacks, and will provide doctors with a much-needed new treatment for this common disease."
Asthma is a chronic disorder of the airways, caused primarily by inflammation and constriction of the smooth muscle in airway walls.
It is commonly triggered by viral respiratory infections, exercise, smoke, cold and allergens such as pollen, mould, animal fur and the house dust mite.
Patients suffer from recurring episodes of wheezing, breathlessness, chest tightness and coughing.
The symptoms can be much worse at night.
Latest figures show that more than 60,000 people across Leicestershire suffer from asthma.
Prevalence of asthma in the UK is among the highest in the world, with 4.3 million adults currently receiving treatment.
The new treatment works by opening narrowed airways and helps to keep them open for at least 24 hours.
It is already licensed for the treatment of patients with chronic lung disease known chronic obstructive pulmonary disease (COPD).
The cost of Spiriva Respimat for people with asthma is £33.50 per 30 days.
Each device delivers enough for 60 puffs – two puffs once a day.
Dr Charles De Wet is medical director UK and Ireland at the pharmaceutical company Boehringer Ingelheim which has developed the treatment.
He said: "We have over 90 years' experience in the field of respiratory medicine and we are committed to bringing new treatment options to patients particularly in areas of high unmet need.
"Launching Spiriva Respimat in asthma is a first for this class of medicine and we are delighted to lead the way."